Contrive Datum Insights has published "Cancer Biomakers Market Size, Share & Industry Analysis, By Profiling technology (Omic Technologies, Imaging Technologies, Immunoassays, Cytogenetics-based Tests), Biomolecule (Genetic Biomarkers, Protein Biomarkers, Glyco-biomarkers), Cancer type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Others), Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, Others), End user (Hospitals and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations), and Regional Forecast, 2026-2034". The study sizes the global cancer biomakers market at USD 25.8 billion in 2025 and projects growth from USD 28.7 billion in 2026 to USD 63.5 billion by 2034, a compound annual growth rate of 10.44% across the forecast period.
Cancer biomarkers are the molecular, genetic, protein and imaging signals measured from a patient's tumor, blood or other tissue to detect cancer, classify its subtype, select a treatment or track how it responds over time. They take the form of laboratory assays, sequencing panels and imaging-based tests run on samples collected in a clinic or hospital, and results feed directly into a treating oncologist's diagnosis and treatment decisions. Buyers are hospital and reference laboratories that run the tests, pharmaceutical and biotechnology companies that use biomarkers to develop and pair companion diagnostics with new therapies, and academic and contract research centers that validate new biomarker candidates.
Expansion of companion diagnostics tied to targeted oncology therapies
Expansion of companion diagnostics tied to targeted oncology therapies is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 10.44% a year, the profiling technology lines exposed to it move fastest: Omic Technologies compounds at 12.21%, taking its share of revenue from 44.98% to 52% and its value from USD 11.61 billion to USD 33.02 billion.
A more favourable outcome is possible. If the bull case assumes faster-than-expected companion-diagnostic approvals and quicker payer adoption of reimbursement for newer liquid-biopsy and multi-omic panels, pulling test volumes higher across every region, 2034 revenue reaches USD 72.39 billion instead of the USD 63.5 billion the base case carries.
Against that, the bear case assumes payers slow reimbursement expansion for newer biomarker tests and adoption of sequencing-based panels in cost-constrained health systems lags the pace assumed in the base case. On that reading 2034 revenue stops at USD 54.61 billion. The weight of the problem sits in Immunoassays: 26% of 2025 revenue growing at 9.45%, well under the market's 10.44%.
Omic Technologies Leads on Both Scale and Growth
Unusually, scale and growth sit in the same place. Omic Technologies holds 44.98% of 2025 revenue (USD 11.61 billion) and still compounds at 12.21%, reaching 52% of the market by 2034. That removes the usual trade-off between defending volume and chasing growth, and it raises what a challenger has to overcome in a market of USD 25.8 billion.
What Else the Report Shows
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Biomolecule | Genetic Biomarkers | 50% · USD 12.9 billion | — |
| Cancer type | Breast Cancer | 26% · USD 6.71 billion | Lung Cancer 12.11% |
| Application | Diagnostics | 45% · USD 11.61 billion | Drug Discovery and Development 12.36% |
| End user | Hospitals and Diagnostic Laboratories | 40% · USD 10.32 billion | Contract Research Organizations 14.74% |
- North America was the largest region in 2025, holding 39% of global revenue at USD 10.06 billion and reaching USD 22.86 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 25% in 2025 to 30% in 2034, with revenue growing from USD 6.45 billion to USD 19.05 billion.
- Middle East and Africa stays the smallest contributor across the period: 4.5% of revenue in 2025 and 4.5% in 2034.
- By profiling technology, the largest line in 2025 was Omic Technologies, at 44.98% of revenue and USD 11.61 billion.
- Omic Technologies is projected to grow at 12.21% over the forecast period, the fastest of any profiling technology line.
- The United States is the largest single country market at USD 8.55 billion in 2025, 33.14% of global revenue.
Coverage runs to five axes, by profiling technology, and by biomolecule, cancer type, application and end user, with a revenue figure and a growth rate for every line in every year from 2020 to 2034, and bear, base and bull cases on the headline total at USD 54.61 billion and USD 72.39 billion by 2034. All five regions are broken out to country level, alongside the competitive landscape and the methodology behind each estimate. The study is delivered as a PDF, and a free sample can be requested.